Abstract：Objective: To analyze the relationship between tumor budding and clinicopathological features and prognosis of prostate cancer (PCa). Methods: The clinical data of 101 patients with PCa who underwent radical resection in the hospital were collected between January 2018 and December 2021.Two pathologists used the tumor budding count and grading method proposed by Ueno et al.to determine the tumor budding of PCa tissue,and Kappa consistency test was used to evaluate the consistency.The relationship between clinicopathological features and tumor budding grading was analyzed among patients with PCa.The survival rate of patients with different tumor budding grades was compared among patients with follow-up time≥2 years. Results: The minimum and maximum tumor budding counts of 101 patients with PCa were 0 and 31,with the median of 4.There were 45 cases of high-grade tumor budding,56 cases of low-grade tumor budding,and 21 cases without budding.The two pathologists had good consistency in judging the tumor budding grading (Kappa coefficient=0.880,P<0.05).Among patients with PCa,the high-grade rate of tumor budding was higher among patients with high TNM stage,high Gleason score,lymph node metastasis,capsular invasion,seminal vesicle invasion and negative E-cadherin expression (P<0.05).62 cases were followed up for ≥2 years,including 26 cases of high-grade tumor budding and 36 cases of low-grade tumor budding.Log-rank test showed that the survival rate of patients with high-grade tumor budding was significantly lower than that of patients with low-grade tumor budding (P<0.05). Conclusion: Tumor budding is closely related to the clinicopathological feature of PCa,and can predict the prognosis of patients with PCa.
[1] Haddad TS,Lugli A,Aherne S,et al.Improving tumor budding reporting in colorectal cancer:a delphi consensus study[J].Virchows Arch,2021,479(3):459-469. [2] Muller F,Lugli A,Dawson H.Tumor budding in colorectal cancer-Information for clinical use and instructions for practical evaluation[J].Pathologe,2022,43(1):45-50. [3] Lugli A,Zlobec I,Berger MD,et al.Tumour budding in solid cancers[J].Nat Rev Clin Oncol,2021,18(2):101-115. [4] Lugli A,Kirsch R,Ajioka Y,et al.Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016[J].Mod Pathol,2017,30(9):1299-1311. [5] Ueno H,Murphy J,Jass JR,et al.Tumour 'budding' as an index to estimate the potential of aggressiveness in rectal cancer[J].Histopathology,2002,40(2):127-132. [6] Kocsmar E,Lotz G,Kiss A,et al.Prognostic impact of tumor budding and EMT in periampullary adenocarcinoma:a quantitative approach[J].Cancer,2020,11(22):6474-6483. [7] 年瑞,李万军,李维华,等.胰腺导管腺癌神经侵犯和肿瘤出芽的临床病理分析[J].临床肿瘤学杂志,2021,26(11):980-984. [8] Mitrovic B,Handley K,Assarzadegan N,et al.Prognostic and predictive value of tumor budding in colorectal cancer[J].clin colorectal cancer.2021,20(3):256-264. [9] Huang T,Bao H,Meng YH,et al.Tumour budding is a novel marker in breast cancer:the clinical application and future prospects[J].Ann Med,2022,54(1):1303-1312. [10] 徐程,张响,姬东泽,等.肿瘤出芽与pT1期胃腺癌临床病理特征的相关性分析[J].临床与实验病理学杂志,2021,37(4):384-388. [11] 卢远响,李文森,肖二卫,等.肿瘤出芽与胰腺神经内分泌瘤临床病理的相关性及预后价值分析[J].中华普通外科杂志,2021,36(7):494-498. [12] Smit MA,van Pelt GW,Terpstra V,et al.Tumour-stroma ratio outperforms tumour budding as biomarker in colon cancer:a cohort study[J].Int Colorectal Dis,2021,36(12):2729-2737. [13] Rau TT,Bettschen E,Buchi C,et al.Prognostic impact of tumor budding in endometrial carcinoma within distinct molecular subgroups[J].Mod Pathol,2021,34(1):222-232. [14] Fuchinoue K,Nemoto T,Shimada H,et al.Immunohistochemical analysis of tumor budding as predictor of lymph node metastasis from superficial esophageal squamous cell carcinoma[J].Esophagus,2020,17(2):168-174.
2023, Vol. 29 
冀公网安备13080202000677号